Castleark Management’s Pfizer PFE Stock Holding History

Castleark Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.5K	Hold	2,971	–	–	﹤0.01%	306
2026 Q1	$83.4K	Hold	2,971	–	–	﹤0.01%	287
2025 Q4	$74K	Hold	2,971	–	–	﹤0.01%	289
2025 Q3	$75.7K	Hold	2,971	–	–	﹤0.01%	278
2025 Q2	$72K	Hold	2,971	–	–	﹤0.01%	269
2025 Q1	$75.3K	Hold	2,971	–	–	﹤0.01%	268
2024 Q4	$78.8K	Sell	2,971 -3,529	-54%	-$95.7K	﹤0.01%	271
2024 Q3	$188K	Hold	6,500	–	–	0.01%	244
2024 Q2	$182K	Hold	6,500	–	–	0.01%	242
2024 Q1	$180K	Hold	6,500	–	–	0.01%	251
2023 Q4	$187K	Hold	6,500	–	–	0.01%	255
2023 Q3	$216K	Hold	6,500	–	–	0.01%	240
2023 Q2	$238K	Hold	6,500	–	–	0.01%	241
2023 Q1	$265K	Hold	6,500	–	–	0.01%	239
2022 Q4	$333K	Hold	6,500	–	–	0.02%	247
2022 Q3	$284K	Hold	6,500	–	–	0.02%	250
2022 Q2	$341K	Hold	6,500	–	–	0.02%	237
2022 Q1	$337K	Hold	6,500	–	–	0.01%	271
2021 Q4	$384K	Hold	6,500	–	–	0.01%	280
2021 Q3	$280K	Hold	6,500	–	–	0.01%	286
2021 Q2	$255K	Hold	6,500	–	–	0.01%	295
2021 Q1	$235K	Hold	6,500	–	–	0.01%	296
2020 Q4	$239K	Sell	6,500 -351	-5%	-$12.9K	0.01%	304
2020 Q3	$239K	Hold	6,851	–	–	0.01%	307
2020 Q2	$213K	Hold	6,851	–	–	0.01%	298
2020 Q1	$212K	Hold	6,851	–	–	0.01%	275
2019 Q4	$255K	Hold	6,851	–	–	0.01%	307
2019 Q3	$234K	Hold	6,851	–	–	0.01%	318
2019 Q2	$282K	Hold	6,851	–	–	0.01%	318
2019 Q1	$276K	Hold	6,851	–	–	0.01%	324
2018 Q4	$284K	Hold	6,851	–	–	0.01%	325
2018 Q3	$286K	Hold	6,851	–	–	0.01%	338
2018 Q2	$236K	Hold	6,851	–	–	0.01%	341
2018 Q1	$231K	Hold	6,851	–	–	0.01%	352
2017 Q4	$235K	Hold	6,851	–	–	0.01%	355
2017 Q3	$232K	Hold	6,851	–	–	0.01%	352
2017 Q2	$218K	Hold	6,851	–	–	0.01%	361
2017 Q1	$222K	Hold	6,851	–	–	0.01%	337
2016 Q4	$211K	Hold	6,851	–	–	0.01%	339
2016 Q3	$220K	Hold	6,851	–	–	0.01%	326
2016 Q2	$229K	Hold	6,851	–	–	0.01%	319
2016 Q1	$193K	Hold	6,851	–	–	0.01%	326
2015 Q4	$210K	Hold	6,851	–	–	0.01%	332
2015 Q3	$204K	Hold	6,851	–	–	0.01%	333
2015 Q2	$218K	Hold	6,851	–	–	0.01%	345
2015 Q1	$226K	Hold	6,851	–	–	0.01%	336
2014 Q4	$202K	Sell	6,851 -1,313,820	-99%	-$37.7M	0.01%	320
2014 Q3	$40.2M	Buy	1,320,671 +1,313,820	+19,177%	+$36.9M	1.14%	28
2014 Q2	$193K	Sell	6,851 -1,313,820	-99%	-$37.5M	0.01%	306
2014 Q1	$40.2M	Sell	1,320,671 -631,357	-32%	-$18.8M	1.14%	28
2013 Q4	$56.7M	Buy	1,952,028 +1,945,177	+28,393%	+$56.6M	1.65%	22
2013 Q3	$192K	Sell	6,851 -2,129,291	-100%	-$57.9M	0.01%	326
2013 Q2	$56.8M	Buy	+2,136,142	New	+$59M	1.88%	21

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Castleark Management's PFE Position: Q2 2026 in Review

Castleark Management held its Pfizer (PFE) position steady in Q2 2026 at 2,971 shares worth $71.5K. The position accounts for ﹤0.01% of the portfolio, ranked #306.

Castleark Management first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $56.8M in Q2 2013. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Castleark Management held 2,971 shares of Pfizer worth $71.5K as of Q2 2026.
Castleark Management left its Pfizer share count unchanged in Q2 2026.
Pfizer made up ﹤0.01% of Castleark Management's portfolio in Q2 2026, its #306 holding.
Castleark Management first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
Castleark Management's Pfizer position peaked at $56.8M in Q2 2013.
2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Castleark Management's 13F filing for Q2 2026, filed 14 Aug 2026.